ClinConnect ClinConnect Logo
Search / Trial NCT05675124

Comparison of Needlescopic vs. Conventional Laparoscopic Adrenalectomy for Tumor Less Than 4 cm

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jan 5, 2023

Trial Information

Current as of July 01, 2025

Not yet recruiting

Keywords

Visual Analogue Scale Post Operative Pain Dosage Of Analgesic Cosmetic

ClinConnect Summary

This clinical trial is looking at two different types of surgery used to remove small tumors from the adrenal glands, which are located on top of the kidneys. The researchers want to find out if a newer, smaller technique called needlescopic adrenalectomy causes less pain and has fewer complications compared to the traditional laparoscopic method. Both surgeries are minimally invasive, meaning they use small incisions, but the needlescopic approach uses even smaller tools.

To participate, individuals must be over 20 years old and have a specific condition called primary aldosteronism, with adrenal tumors that are less than 4 centimeters in size. However, those over 80 years old or with certain health issues, like severe heart disease or active substance addiction, won’t be eligible. Participants will have the opportunity to contribute to important research that could improve surgical outcomes for future patients. If you think you might qualify and are interested in learning more, please reach out to the research team for more details.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Over the age of 20 years old.
  • 2. Primary aldosteronism with unilateral adrenal lesions smaller than 4 cm
  • 3. Indications for laparoscopic surgery.
  • 4. Informed consent
  • Exclusion Criteria:
  • 1. Over 80 years old
  • 2. Suspected adrenal malignancy or pheochromocytoma
  • 3. Other concurrent surgery
  • 4. Patients who underwent bilateral adrenal tumor resection at the same time
  • 5. History of peritonitis or having undergoing major ipsilateral abdominal surgery.
  • 6. American Society of Anesthesiologists (ASA) Class III or IV (with severe cardiovascular disease, uncontrolled hypertension, diabetes, chronic pulmonary obstructive pulmonary disease, morbid obesity (BMI \> 40), dialysis patients, myocardial infarction, stroke, coronary artery disease, liver or coagulation dysfunction, etc.)
  • 7. Opioid addiction
  • 8. Patient have side effects from taking of acetaminophen, celecoxib or opioids
  • 9. Acute intoxication of alcohol, sleep aids, anesthetics, centrally acting analgesics, opium or psychotropic drugs has occurred.
  • 10. Patients using monoamine oxidase inhibitors (MAOIs) concurrently or within the past 14 days.
  • 11. Patients with chronic pain or respiratory depression (such as chronic obstructive pulmonary disease)
  • 12. Pregnancy

About National Taiwan University Hospital

National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.

Locations

Taipei, , Taiwan

Taipei, , Taiwan

Patients applied

0 patients applied

Trial Officials

Jeff Chueh

Principal Investigator

Dep. of Urology, NTUH

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials